Antidepressants

REL-1017 by Relmada Therapeutics: A NMDA Receptor Antagonists - Global Emerging Insight and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 18, 2021
Pharmaceutical, Health, Mental health, Branches of biology, NMDA receptor antagonists, Antidepressants, Glutamate, NMDA receptor

The "REL-1017 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "REL-1017 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • REL-1017 acts as NMDA receptor antagonists and is being developed Relmada Therapeutics.
  • "REL-1017 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Seltorexant: An Innovative Selective Orexin 2 Receptor Antagonist Under Development for the Treatment of Major Depressive Disorder - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Pharmaceutical, Health, Mental health, Antidepressants, Psychoactive drugs, Drugs, Branches of biology, Seltorexant, Orexin, Major depressive disorder, Depressive, TS-121, BTRX-335140

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of Major Depressive Disorder.

Key Points: 
  • Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of Major Depressive Disorder.
  • "Seltorexant- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Which are the late-stage emerging therapies under development for the treatment of Major Depressive Disorder?

AXS-05: A Novel, Oral, Patent-Protected, Investigational NMDA Receptor Antagonist with Multimodal Activity - Global Emerging Insight and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Health, Pharmaceutical, Branches of biology, Antidepressants, Drugs, NMDA receptor antagonists, Bupropion/dextromethorphan, NMDA receptor

The "AXS-05 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "AXS-05 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • AXS-05 is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of major depressive disorder and other central nervous system (CNS) disorders.
  • "AXS-05 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Myconic Capital Corp. Signs Letter of Intent for Acquisition of Mindscape Ketamine & Infusions Therapy, PLLC

Retrieved on: 
Wednesday, March 10, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, NMDA receptor antagonists, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.

Key Points: 
  • After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.
  • The Houston-based clinic, which administers ketamine through intravenous therapy (IV), is characterized by its spa-like atmosphere designed to put patients at ease.
  • Ketamine was first synthesized in 1962, and was successfully patented as a human anaesthetic in the United States in 1966.
  • We look forward to exploring the potential directions in which we can take Mindscape as ketamine treatments continue to gain acceptance and popularity across the United States.

Esketamine DPI: An NMDA Receptor Antagonists Being Developed by Celon Pharma - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021
Health, Pharmaceutical, Drugs, Psychoactive drugs, Branches of biology, NMDA receptor antagonists, General anesthetics, Antidepressants, Amines, Nicotinic antagonists, Esketamine, NMDA receptor, Ketamine

The "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • It acts as NMDA receptor antagonists and is being developed by Celon Pharma.
  • "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report provides comprehensive insights about an investigational product for Treatment Resistant Bipolar Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB

Retrieved on: 
Wednesday, March 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Dissociative drugs, General anesthetics, Sedatives, Antidepressants, Nicotinic antagonists, Ketamine

Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.

Key Points: 
  • Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.
  • On March 1, 2021 Ehave successfully filed its application to uplist its shares on the OTCQB market.
  • The KetaDASH www.ketadash.com platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously.
  • Ben Kaplan, Chief Executive Officer of Ehave commented, The application for a U. S. Trademark is a key step in protecting our valuable brand and psychedelic medicine assets, most notably KetaDASH.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 1, 2021
Antidepressants, Bupropion/dextromethorphan, Migraine, Food and Drug Administration, Major depressive disorder, Health care, Medicine, Health

Depression: Axsome has submitted a New Drug Application (NDA) to the FDA for AXS-05 for the treatment of MDD.

Key Points: 
  • Depression: Axsome has submitted a New Drug Application (NDA) to the FDA for AXS-05 for the treatment of MDD.
  • Axsome previously announced positive results from a Phase 2 trial of AXS-05 for smoking cessation treatment conducted under a research collaboration between Axsome and Duke University.
  • In December 2020, Axsome announced positive results from the MOVEMENT Phase 3 long-term trial of AXS-07 in the acute treatment of migraine.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2020 financial results as well as to provide a corporate update.

Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder

Retrieved on: 
Wednesday, February 24, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Otsuka Pharmaceutical, MDD, Antidepressants, Atypical antipsychotics, Companies, Economy of Japan, Combination drugs, the Otsuka and Click Therapeutic Collaboration, Otsuka, Click

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy.

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy.
  • Otsuka and Click will collaborate with Verily, a subsidiary of Alphabet, to execute the trial as a fully remote trial.
  • The collaboration also enables the trial to proceed efficiently and safely in the face of the unique market challenges presented by COVID-19.
  • Otsuka has committed to fully fund development of Clicks novel mobile application for MDD, and to commercialize upon achievement of regulatory approvals.

Axsome Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, February 19, 2021
Psychiatric diagnosis, Antidepressants, Health care, Bupropion/dextromethorphan, Health, Smoking cessation, Major depressive disorder, Clinical medicine

Cowen 41st Annual Health Care Conference, on March 1, 2021 at 11:00 AM Eastern Time.

Key Points: 
  • Cowen 41st Annual Health Care Conference, on March 1, 2021 at 11:00 AM Eastern Time.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.
  • For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines.
  • AXS-05 is being developed for major depressive disorder (MDD), Alzheimers disease (AD) agitation, and as a treatment for smoking cessation.

Flying is Now Easier Thanks to New Phase Blends' CBD-based Sleep Aid

Retrieved on: 
Friday, February 5, 2021
Branches of biology, Biology, Circadian rhythm, Antidepressants, Antioxidants, Melatonin, Sleep, Patent, Technology Student Association

WEST PALM BEACH, Fla., Feb. 5, 2021 /PRNewswire/ -- The popular CBD-based sleep aid called 'sleep' by New Phase Blends is about to be released in small, travel sized packaging.

Key Points: 
  • WEST PALM BEACH, Fla., Feb. 5, 2021 /PRNewswire/ -- The popular CBD-based sleep aid called 'sleep' by New Phase Blends is about to be released in small, travel sized packaging.
  • These natural sleep aids meet TSA guidelines for flying with CBD products.
  • People can now help ease their flying anxiety, thanks to recently changed TSA guidelines.
  • It has a patent-pending status through the United States Patent and Trademark Office for the use of CBD and melatonin as a sleep aid.